Why Resmed (RMD) Stock Is Up Today
This article explains why Resmed (RMD) stock is experiencing an increase today. It will likely detail factors contributing to the positive movement, such as company news, analyst upgrades, or market trends.
ERAS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of ...
Faruqi & Faruqi, LLP is investigating potential claims against Erasca, Inc. (ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The investigation stems from allegations that Erasca made false or misleading statements regarding its drug candidate ERAS-007, specifically concerning its preclinical data and comparison to a competitor's product, leading to significant stock price drops. Investors are encouraged to contact the firm by the August 10, 2026 deadline to discuss their legal rights and potentially serve as lead plaintiff in a class action lawsuit.
Precision Trading with Resmed Inc. (RMD) Risk Zones
This article analyzes Resmed Inc. (RMD), highlighting a strong near-to-mid-term sentiment despite a weak long-term outlook. It identifies a mid-channel oscillation pattern and presents an exceptional 33.1:1 risk-reward setup targeting a 9.6% gain against 0.3% risk. The piece outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
INGN - Inogen Inc Volatility & Greeks
This article provides a detailed overview of Inogen Inc (INGN) financial data, including its stock performance, volatility metrics, and various financial ratios. It covers key figures such as market capitalization, sales, earnings per share, insider and institutional ownership, and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook
ResMed (RMD) experienced a 5.6% stock increase despite being removed from several Russell growth indices in late June 2026. This uplift is attributed to a more optimistic outlook from analysts, who have upgraded rankings and raised profit estimates for the company. The article suggests that while index removal affects investment flows, the improving analyst sentiment could significantly reshape ResMed's investment narrative and risk-reward profile, especially with its upcoming Q4 fiscal 2026 earnings report on August 6.
TFX - Teleflex Incorporated Earnings
This article provides a comprehensive snapshot of Teleflex Incorporated (TFX) financial data and key performance indicators. It covers market valuation, income statement figures, dividend information, analyst estimates, insider and institutional ownership, and various stock performance metrics. The data reflects the company's financial health and market activity up to the last close on July 2nd.
Ord Minnett Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
Ord Minnett has reiterated its Buy rating for Resmed Inc CHESS Depositary Interests (RMD) and set a price target of A$36.80. The analyst consensus on RMD remains a Strong Buy, with an average price target of A$41.05. The company recently reported strong quarterly earnings, with revenue of A$1.42 billion and a net profit of A$395.1 million.
Ord Minnett Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
Ord Minnett has reiterated its Buy rating for Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$36.80. The broader analyst consensus for RMD is a Strong Buy, with an average price target of A$41.05. Resmed recently reported strong quarterly results, with revenue of A$1.42 billion and net profit of A$395.1 million for the quarter ending March 31.
ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook
ResMed (RMD) saw its stock rise by 5.6% following its removal from several Russell growth indices, including the Russell 1000 Growth and Russell Midcap Growth benchmarks. This occurred as analysts became more optimistic about the company's earnings outlook, with upgraded rankings and higher profit estimates. The article suggests that while index removal primarily affects index flows, the improving analyst sentiment and upcoming Q4 fiscal 2026 earnings report on August 6 could significantly reshape ResMed's investment narrative.
Why ResMed (RMD) Stock Is Trading Up Today
Shares of medical device company ResMed (RMD) rose 3.7% after being added to Goldman Sachs' APAC Conviction List, signaling renewed confidence in the company's growth and momentum. This positive movement comes despite a recent downgrade by Morgan Stanley due to concerns about profit margins, competition, and the impact of GLP-1 weight-loss drugs on the sleep apnea market. ResMed's stock is still down 14.5% year-to-date and 28.8% below its 52-week high.
Why ResMed (RMD) Stock Is Trading Up Today
Shares of medical device company ResMed (RMD) jumped 3.7% after being added to Goldman Sachs' APAC Conviction List, signaling renewed confidence in the company's growth trajectory ahead of its Q4 fiscal 2026 results. This positive movement comes despite a recent downgrade by Morgan Stanley due to concerns about profit margins, competition, and the impact of GLP-1 weight-loss drugs on sleep apnea treatment demand. ResMed's stock is still down 14.5% year-to-date and 28.8% from its 52-week high.
Why ResMed (RMD) Stock Is Trading Up Today
ResMed (RMD) stock jumped 3.7% after being added to Goldman Sachs' APAC Conviction List, signaling renewed confidence in the company's growth, especially with Q4 fiscal 2026 results due in August. This positive sentiment follows a broader healthcare sector gain, despite a recent downgrade by Morgan Stanley due to concerns over profit margins, competitor re-entry, and the impact of GLP-1 weight-loss drugs. ResMed's shares are down 14.5% year-to-date and trading significantly below their 52-week high.
ResMed Inc. stock rises Thursday, outperforms market
ResMed Inc. (RMD) stock surged by 4.24% on Thursday, closing at $209.63, outperforming a mixed market session. This marks the second consecutive day of gains for ResMed, as the S&P 500 remained mostly unchanged and the Dow Jones Industrial Average rose by 1.14%.
RMD - Resmed Inc Latest SEC Filings
This article provides an overview of ResMed Inc. (RMD)'s latest financial data and stock performance as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, dividend information, and various financial ratios. The report also details insider and institutional ownership, profitability margins, and historical stock performance.
VMD - Viemed Healthcare Inc Earnings
This article provides a detailed financial overview of Viemed Healthcare Inc (VMD), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics like EPS growth, insider and institutional ownership, profitability margins, and stock performance over different periods. The data covers real-time stock information and historical financial statistics for potential investors.
RMD - Resmed Inc Options
This article provides a detailed financial overview of Resmed Inc (RMD), a company in the medical instruments and supplies sector. It covers various financial metrics including market capitalization, income, sales, dividend information, P/E ratios, growth rates, and institutional ownership. The data highlights recent performance, analyst recommendations, and key valuation figures for investors.
ResMed (RMD) Added to Goldman Sachs' APAC Conviction List
Goldman Sachs has included ResMed (RMD) in its APAC Conviction List, maintaining a Buy rating and setting a price target of A$46.70. This endorsement is driven by anticipated sustained growth in continuous airway pressure therapy due to increasing sleep apnea diagnoses and an aging population, coupled with ResMed's focus on digital health. Despite significant insider selling over the past three months, the company boasts a high GF Score™ of 90 and a P/E ratio close to its historical low, suggesting potential undervaluation.
ResMed Inc. stock rises Wednesday, outperforms market
ResMed Inc. (RMD) shares rose 3.19% on Wednesday, closing at $201.10. This performance outpaced the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average experienced declines. The increase marked the end of a two-day losing streak for the stock.
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
Wall Street analysts project ResMed (RMD) could see a 28.2% upside, with a mean price target of $249.86. While price targets are viewed with skepticism, the stock's Zacks Rank #2 (Buy) and positive earnings estimate revisions suggest potential near-term upside. Investors are advised to consider multiple factors beyond just price targets.
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
Sarepta Therapeutics has secured an early 2027 FDA decision for full approval of its Duchenne muscular dystrophy exon-skipping therapies, Amondys 45 and Vyondys 53, despite their failure to improve motor function in a confirmatory Phase 3 trial. The FDA's acceptance of the application is seen as a positive signal by analysts, especially given Sarepta's submission includes substantial real-world evidence and favorable safety profiles. This move comes amidst broader changes at the FDA, with analysts suggesting a potentially more lenient regulatory environment for rare diseases.
ResMed (NYSE: RMD) reports 1.95% stake in Nyxoah — 1.94M shares
ResMed Inc. has filed an amended Schedule 13G/A, disclosing a 1.95% beneficial ownership stake in Nyxoah SA, totaling 1,943,828 ordinary shares. This passive investment is below the 5% threshold and signifies no intent to control or influence Nyxoah, consistent with administrative disclosure requirements. The filing by CFO Aaron Bloomer confirms the share count as of June 10, 2026, and is considered an administrative update.
Nyxoah adds 146,531 shares as voting rights reach 100.1 million
Nyxoah (Nasdaq: NYXH) has updated its share capital and voting rights as of June 30, 2026, following the issuance of 146,531 new shares from exercised restricted share units. The company's share capital is now EUR 7,075,152.31, with 100,072,815 ordinary shares and an equal number of voting rights. This announcement also detailed outstanding subscription rights and convertible bonds, which represent potential future dilution.
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
ResMed is scheduled to report its fourth quarter and full fiscal year 2026 earnings on Thursday, August 6, 2026, after the market closes. The company will also host a live webcast and conference call to discuss its financial results, which will be accessible via its investor relations website.
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
Resmed (NYSE: RMD, ASX: RMD) announced its plan to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results, which will be accessible via their investor relations website. A replay will also be available on their website and via phone until August 20, 2026.
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
Resmed (NYSE: RMD, ASX: RMD) announced it will release its fourth quarter fiscal year 2026 financial and operational results on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide additional information. The webcast, available on Resmed's investor relations website, will also have a replay accessible approximately two hours after the live event.
Resmed sets Aug. 6 webcast for fiscal Q4 results
Resmed (NYSE: RMD) announced it will release its fourth quarter fiscal year 2026 financial and operational results on Thursday, August 6, 2026, after the NYSE closes. Management will host an earnings webcast at 1:30 p.m. PT / 4:30 p.m. ET, accessible via its investor relations website, with replay options available. The announcement also detailed phone replay access until August 20, 2026.
ResMed Inc. stock falls Tuesday, underperforms market
ResMed Inc. stock dropped 1.79% on Tuesday, closing at $194.88, despite an overall strong performance in the stock market. The S&P 500 Index rose 0.79%, and the Dow Jones Industrial Average increased by 0.26%. This marks the second consecutive day of losses for ResMed Inc. shares.
ResMed leads sleep apnea market with strong growth and margin improvements, rated Buy with 12% safety margin.
ResMed (RMD) holds a dominant 62% share in the sleep apnea market, which analysts believe has significant growth potential due to its under-penetration. The company's business model, characterized by recurring revenue from consumables and strong brand loyalty, supports consistent financial performance marked by over a decade of sales and earnings growth. Recent CMS exclusions and tariff exemptions are further enhancing its margins, leading to a "Buy" recommendation with a 12% safety margin.
Nyxoah sees Orin Hirchman cross 10% voting rights threshold, Resmed drops below 3%.
Nyxoah SA announced that Orin Hirchman, through controlled entities, has acquired 14.55% of voting rights as of June 10, 2026, exceeding the 10% disclosure threshold. Concurrently, Resmed Inc. reduced its stake to 1.95%, falling below the 3% threshold. These shifts in significant shareholders could influence company governance and investor dynamics.
ResMed Inc.(NYSE: RMD) dropped from Russell 3000 Growth Benchmark
ResMed Inc. (NYSE:RMD) has been removed from the Russell 3000 Growth Benchmark, as announced on June 28, 2026. This exclusion also extends to other related benchmarks such as the Russell Midcap Growth, Russell 3000E Growth, Russell 1000 Growth, and Russell 1000 Growth-Defensive Index. The action follows a period where the company's stock experienced price target adjustments and downgrades from analysts.
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging Erasca, Inc. (ERAS) shareholders who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Erasca made misleading statements concerning its drug candidate ERAS-0015, which was accused of patent infringement and trade secret misappropriation by Revolution Medicines, and also involved a patient death during preliminary Phase 1 clinical trials, causing significant stock price drops. Investors have until August 10, 2026, to file a lead plaintiff motion.
Are Options Traders Betting on a Big Move in ResMed Stock?
Options traders are showing high implied volatility for ResMed Inc. (RMD) stock, suggesting expectations of a significant price movement. Despite this, analysts currently rate ResMed as a Zacks Rank #3 (Hold), with recent earnings estimate revisions indicating a slight increase for the current quarter. This discrepancy between options market activity and analyst sentiment might present a potential trading opportunity for seasoned options traders looking to sell premium.
Why Inspire Medical Systems (INSP) Is Up 10.6% After Russell Index Reclassification To Small Cap
Inspire Medical Systems (INSP) saw a 10.6% increase after being reclassified from the Russell 1000 to smaller-cap and value-oriented Russell indices in late June 2026. This reclassification could shift the company's investor base and position sizing, influencing its investment narrative amidst ongoing challenges like slower growth and execution risks with its Inspire V rollout. Despite these hurdles, data from SLEEP 2026 suggests the new system could sustain physician confidence and payer support, with analysts projecting $987.4 million revenue and $67.1 million earnings by 2029 for Inspire, while some bearish analysts project lower figures.
ResMed Inc.(NYSE: RMD) dropped from Russell 1000 Growth Benchmark
ResMed Inc. (NYSE:RMD) has been removed from the Russell 1000 Growth Benchmark. The medical equipment company specializes in diagnosing and treating respiratory disorders, with a significant portion of its net sales coming from medical devices, masks, and SaaS solutions. The article also provides recent news and analyst ratings for RMD.
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
The article focuses on the "Enterprise value to EBIT forward" metric for ResMed Inc. CHESS Depositary Interests (RMEA) on the Munich Stock Exchange. It appears to be a financial data page from TradingView, displaying various market data, community features, and tools related to the stock. The content itself seems to be a template or placeholder for financial information regarding RMEA, rather than a narrative article.
Price to earnings forward of ResMed Inc. – NYSE:RMD
This article provides the "Price to earnings forward" value for ResMed Inc. (NYSE:RMD). It appears to be a financial data point from TradingView, which aggregates market data, reference data, and SEC filings. The specific numerical value for the "Price to earnings forward" is not presented in the provided content.
Price to earnings forward of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – MUN:RMEA
This article provides financial information for ResMed Inc. CHESS Depositary Interests (RMEA) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It is a data snapshot provided by TradingView, indicating that the market is currently closed with no trades.
Price to sales forward of ResMed Inc. – NYSE:RMD
This article provides access to the "Price to sales forward" financial metric for ResMed Inc. (NYSE: RMD) on the TradingView platform. It details the company's stock information, along with links to various financial data, news, and community features available on TradingView. The content focuses on directing users to the specific financial data point for ResMed within the platform.
ResMed Inc. stock rises Thursday, outperforms market
ResMed Inc. (RMD) stock rose 1.07% to $198.60 on Thursday, outperforming the mixed market session. The Dow Jones Industrial Average gained 0.14%, while the S&P 500 Index fell 0.01%. This marks the third consecutive day of gains for ResMed's stock.
ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign?
ResMed (RMD) stock has dropped 20% in 2026, trading 33% below its 52-week high despite strong Q3 2026 results including 11% revenue growth, 290 basis points gross margin expansion, and 21% non-GAAP EPS growth. Analysts maintain buy ratings, with a mean target implying a 33% upside, largely due to new data suggesting GLP-1 co-prescriptions increase PAP adherence. TIKR's model indicates a 41% upside by 2030, driven by this GLP-1 data, the acquisition of Noctrix Health, and substantial share buybacks.
Price to book forward of ResMed Inc. – NYSE:RMD
This article provides financial information for ResMed Inc. (NYSE: RMD), specifically focusing on its "Price to book forward" metric. The content highlights that these financial data points are made by humans and are available through TradingView, including market and reference data from ICE Data Services and FactSet.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who suffered losses. The lawsuit alleges securities fraud and other unlawful business practices by Erasca and its officers/directors. Investors who purchased Erasca securities during the Class Period have until August 10, 2026, to apply to be lead plaintiff.
Enterprise value to EBITDA forward of ResMed Inc. – NYSE:RMD
This article focuses on the enterprise value to EBITDA forward for ResMed Inc. (NYSE: RMD). It presents financial data within the TradingView platform context, indicating a specific financial metric for ResMed.
Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?
ResMed Inc. (RMD) is positioned as a long-term winner due to continued expansion in the Obstructive Sleep Apnea (OSA) market, supported by factors like GLP-1 adoption and wearable technologies. KeyBanc maintained an Overweight rating on RMD shares, adjusting its price target to $266. Additionally, ResMed recently acquired Noctrix Health, Inc., expanding its sleep health portfolio to include treatments for Restless Legs Syndrome.
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
This article identifies Haleon plc (NYSE:HLN) as one of the best healthcare stocks, highlighting its Price Target Upside of 26.79%. It details Haleon's plans to invest approximately GBP 175 million (~$233 million) to expand its presence in India, focusing on a new oral health manufacturing facility and strengthening distribution. The investment aims to enhance supply capabilities and expand the reach of brands like Sensodyne and Parodontax in a key growth market.
ResMed Inc. stock rises Wednesday, outperforms market
ResMed Inc. (RMD) saw its stock price increase by 2.74% on Wednesday, closing at $196.50. This performance outpaced the broader market, which experienced a mixed trading session with the Dow Jones Industrial Average rising and the S&P 500 Index falling. This marks the second consecutive day of gains for ResMed's stock.
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
This article, part of a larger list, highlights Haleon plc (NYSE: HLN) as one of the top healthcare stocks to buy. It details analyst actions, including a rating downgrade by Rothschild & Co Redburn, and the company's strategic investment of GBP 175 million to expand in India, focusing on a new oral health manufacturing facility and distribution network improvements. The investment aims to enhance supply capabilities and increase global access to its consumer healthcare products.
Did Morgan Stanley’s GLP-1 Downgrade Just Shift ResMed's (RMD) Investment Narrative?
Morgan Stanley downgraded ResMed due to concerns that GLP-1 weight-loss drugs and Philips' return to the PAP market could impact ResMed's growth and margins. This downgrade highlights how quickly the investment sentiment for sleep and respiratory care providers can change, forcing a reassessment of ResMed's investment narrative. While ResMed's current business shows financial resilience, the long-term impact of evolving treatments and tougher competition remains a key watchpoint.
Resmed Inc (RMD) Institutional Confidence
Resmed Inc (RMD) has an institutional shareholding score of 5.00, placing it 109th out of 203 companies in the Healthcare Equipment & Supplies industry. Institutional investors hold 69.00% of the company's shares, marking a 3.69% quarter-over-quarter increase. ETHSX is the largest institutional shareholder, holding 1.10M shares and increasing its stake by 5832.20%.
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis
Resmed Inc (RMD) currently holds a strong financial health score of 9.76 out of 10, ranking first in its industry. The company demonstrated robust financial status and high operating efficiency, with a recent quarterly revenue of $1.43 billion showing a 10.81% year-over-year increase, and net profit growing by 9.23% year-over-year. This analysis highlights RMD's excellent performance in its sector regarding profitability and financial stability.
